<!DOCTYPE html>
<html lang="en">
<head>
    <!-- Google tag (gtag.js) -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-XE3Q1ZF9J3"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());
      gtag('config', 'G-XE3Q1ZF9J3');
    </script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antibodies from Thin Air | AI Drug Discovery | InventCures</title>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        :root {
            --jam2: #E63946;
            --chai2: #457B9D;
            --origin1: #2A9D8F;
            --rfantibody: #E9C46A;
            --lx2: #9467BD;
            --accent: #1D3557;
            --text: #333333;
            --light-bg: #F8F8F8;
            --border: #E0E0E0;
        }
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: 'Georgia', serif; line-height: 1.7; color: var(--text); max-width: 720px; margin: 0 auto; padding: 40px 20px; background: #fff; }
        .back-link { display: inline-block; margin-bottom: 1.5rem; color: var(--accent); text-decoration: none; font-size: 0.9em; }
        .back-link:hover { text-decoration: underline; }
        h1 { font-size: 2.4em; color: var(--accent); margin-bottom: 0.3em; line-height: 1.2; }
        .subtitle { font-size: 1.2em; color: #666; margin-bottom: 0.5em; }
        .date { font-style: italic; color: #888; margin-bottom: 1em; }
        .update-notice { background: linear-gradient(135deg, #fff3cd 0%, #ffeeba 100%); border-left: 4px solid #ffc107; padding: 1em 1.5em; margin: 1.5em 0; border-radius: 0 8px 8px 0; font-size: 0.95em; }
        .update-notice strong { color: #856404; }
        .update-notice p { margin: 0.5em 0; }
        .pdf-notice { background: linear-gradient(135deg, #f0f7ff 0%, #e8f4f8 100%); border-left: 4px solid var(--chai2); padding: 1em 1.5em; margin: 1.5em 0; border-radius: 0 8px 8px 0; font-size: 0.95em; }
        .pdf-notice p { margin: 0; }
        .pdf-notice a { color: var(--accent); font-weight: 600; }
        h2 { font-size: 1.6em; color: var(--accent); margin-top: 2em; margin-bottom: 0.8em; border-bottom: 2px solid var(--border); padding-bottom: 0.3em; }
        h3 { font-size: 1.2em; color: var(--text); margin-top: 1.5em; margin-bottom: 0.5em; }
        p { margin-bottom: 1.2em; }
        .lead { font-size: 1.15em; line-height: 1.8; }
        .primer-section { background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-left: 4px solid var(--accent); padding: 1.5em 2em; margin: 1.5em 0 2.5em 0; border-radius: 0 12px 12px 0; }
        .primer-section h2 { border-bottom: none; margin-top: 0; color: var(--accent); }
        .antibody-diagram { text-align: center; margin: 1.5em 0; padding: 1em; background: white; border-radius: 8px; }
        .antibody-diagram svg { max-width: 400px; height: auto; }
        .platform-card { border-left: 4px solid var(--accent); background: var(--light-bg); padding: 1.2em 1.5em; margin: 1.5em 0; border-radius: 0 8px 8px 0; }
        .platform-card.jam2 { border-color: var(--jam2); }
        .platform-card.chai2 { border-color: var(--chai2); }
        .platform-card.origin1 { border-color: var(--origin1); }
        .platform-card.rfantibody { border-color: var(--rfantibody); }
        .platform-card.lx2 { border-color: var(--lx2); }
        .platform-card h3 { margin-top: 0; }
        .platform-card .tagline { font-size: 0.85em; color: #666; font-style: italic; }
        .stat-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1em; margin: 1.5em 0; }
        .stat-box { text-align: center; padding: 1em; background: var(--light-bg); border-radius: 8px; }
        .stat-box .number { font-size: 1.8em; font-weight: 700; color: var(--accent); }
        .stat-box .label { font-size: 0.85em; color: #666; }
        .chart-container { background: var(--light-bg); padding: 1.5em; border-radius: 12px; margin: 2em 0; }
        .chart-container h4 { text-align: center; margin-bottom: 1em; color: var(--accent); font-size: 1.1em; }
        .chart-container .source { font-size: 0.8em; color: #888; text-align: right; margin-top: 0.5em; }
        .chart-wrapper { position: relative; height: 350px; }
        table { width: 100%; border-collapse: collapse; margin: 1.5em 0; font-size: 0.95em; }
        th, td { padding: 0.8em 1em; text-align: left; border-bottom: 1px solid var(--border); }
        th { background: var(--accent); color: white; font-weight: 600; }
        tr:nth-child(even) { background: var(--light-bg); }
        .lx2-callout { background: linear-gradient(135deg, var(--lx2) 0%, #6a3d9a 100%); color: white; padding: 1.5em 2em; border-radius: 12px; margin: 2em 0; }
        .lx2-callout h3 { color: white; margin-top: 0; }
        .oncology-section { border-top: 3px solid var(--jam2); margin-top: 2.5em; padding-top: 1em; }
        .target-category { font-size: 0.85em; text-transform: uppercase; letter-spacing: 0.05em; color: #666; margin-top: 2em; margin-bottom: 0.5em; }
        .caveat-box { border: 2px solid #E63946; background: rgba(230, 57, 70, 0.05); padding: 1.5em; border-radius: 8px; margin: 2em 0; }
        .caveat-box h3 { color: #E63946; margin-top: 0; }
        ul { margin: 1em 0 1em 1.5em; }
        li { margin-bottom: 0.5em; }
        .pipeline-viz { display: flex; justify-content: space-between; align-items: center; margin: 2em 0; overflow-x: auto; padding: 1em 0; }
        .pipeline-stage { flex: 1; min-width: 90px; text-align: center; padding: 0.8em 0.5em; margin: 0 0.2em; border-radius: 8px; font-size: 0.8em; position: relative; }
        .pipeline-stage.done { background: rgba(42, 157, 143, 0.2); border: 2px solid var(--origin1); }
        .pipeline-stage.partial { background: rgba(233, 196, 106, 0.2); border: 2px solid var(--rfantibody); }
        .pipeline-stage.lx2-done { background: rgba(148, 103, 189, 0.2); border: 2px solid var(--lx2); }
        .pipeline-stage.future { background: rgba(128, 128, 128, 0.1); border: 2px dashed #999; color: #666; }
        .pipeline-stage::after { content: '\2192'; position: absolute; right: -0.8em; top: 50%; transform: translateY(-50%); color: #999; }
        .pipeline-stage:last-child::after { content: ''; }
        blockquote { border-left: 4px solid var(--chai2); padding-left: 1.5em; margin: 1.5em 0; font-style: italic; color: #555; }
        .footer { margin-top: 3em; padding-top: 2em; border-top: 1px solid var(--border); font-size: 0.9em; color: #666; font-style: italic; }
        @media (max-width: 600px) { .stat-grid { grid-template-columns: 1fr; } }
    </style>
</head>
<body>
    <a href="/" class="back-link">&larr; Back to Home</a>
    <article>
        <h1>Antibodies from Thin Air</h1>
        <p class="subtitle">Five AI Platforms Are Rewriting the Rules of Cancer Drug Discovery&mdash;And One Just Tested Immunogenicity</p>
        <p class="date">January 2026 (Updated)</p>

        <div class="update-notice">
            <p><strong>UPDATE:</strong> Was made aware of <strong>Latent-X2</strong> by the Latent Labs team. Incorporated their results and re-ran my analysis pipeline to generate this new blog post &amp; technical report.</p>
            <p>Key additions: First-ever immunogenicity data on AI-designed antibodies, macrocyclic peptide design capability, and the tightest binding affinity reported (26.2 pM).</p>
        </div>

        <div class="pdf-notice">
            <p>This post is intended to be brief and accessible to a lay audience. For a more scientific and detailed exposition, <a href="/files/v5_denovo_antibody_design_comparison.pdf" target="_blank">read the full technical report (PDF)</a>.</p>
        </div>

        <div class="primer-section">
            <h2>A Quick Primer: What Are Antibodies, Anyway?</h2>
            <p>Before we dive into the AI revolution, let's talk about what we're actually designing.</p>
            <p>Antibodies are Y-shaped proteins your immune system makes to fight infections. Each antibody is exquisitely specific&mdash;it recognizes one target (an "antigen") and grabs onto it like a lock-and-key. Your body can generate billions of different antibodies, each with a unique binding site.</p>
            <div class="antibody-diagram">
                <svg viewBox="0 0 400 300" xmlns="http://www.w3.org/2000/svg">
                    <path d="M200 280 L200 180 L120 100 L100 80 L110 60 L130 60 L140 80 L160 120 L200 180 L240 120 L260 80 L270 60 L290 60 L300 80 L280 100 L200 180" fill="#E8F0F8" stroke="#1D3557" stroke-width="3"/>
                    <circle cx="120" cy="70" r="15" fill="#E63946"/>
                    <circle cx="280" cy="70" r="15" fill="#E63946"/>
                    <circle cx="80" cy="40" r="20" fill="#2A9D8F" opacity="0.7"/>
                    <text x="320" y="75" font-size="12" fill="#333">Variable Region (Fab)</text>
                    <text x="220" y="250" font-size="12" fill="#333">Constant Region (Fc)</text>
                    <text x="120" y="45" font-size="10" fill="#E63946" font-weight="bold">CDRs</text>
                    <text x="280" y="45" font-size="10" fill="#E63946" font-weight="bold">CDRs</text>
                </svg>
            </div>
            <p>Pharma companies figured out they could turn antibodies into drugs: blocking cancer signals (Herceptin), unleashing immunity on tumors (Keytruda), or neutralizing inflammatory molecules (Humira).</p>
            <p>The problem? Making these antibodies has been stuck in the 1970s. Inject mice, wait, hope. This takes 12&ndash;24 months. Most campaigns fail.</p>
            <h3>The New Way: Design from First Principles</h3>
            <p>What if you could skip the mice entirely? That's what "de novo" antibody design promises. You specify exactly where on the target you want to bind, and software generates protein sequences that fold into antibodies hitting that exact spot. Until recently, this was science fiction. Now it's not.</p>
        </div>

        <h2>The $200 Billion Shakeup</h2>
        <p class="lead">The antibody business has a dirty secret.</p>
        <p>Behind the $200 billion market, there's a process that would embarrass a medieval alchemist. Inject mice, wait, hope. That's basically it.</p>
        <p><strong>Five groups just demonstrated something different.</strong></p>
        <p>Using generative AI&mdash;the same class of technology behind ChatGPT and Midjourney&mdash;they've shown you can design antibodies <em>de novo</em>. From scratch. No mice, no phage display, no hybridomas.</p>

        <div class="stat-grid">
            <div class="stat-box"><div class="number">15-50%</div><div class="label">Hit Rates</div></div>
            <div class="stat-box"><div class="number">4-8 wks</div><div class="label">Timeline</div></div>
            <div class="stat-box"><div class="number">First</div><div class="label">Immunogenicity Data</div></div>
        </div>

        <p>The most striking results?</p>
        <ul>
            <li>One platform designed the <strong>first-ever functional GPCR agonist antibody</strong></li>
            <li>Another achieved <strong>26.2 picomolar binding</strong>&mdash;the tightest affinity reported</li>
            <li>And for the first time, someone actually <em>tested</em> whether AI-designed antibodies trigger immune responses. Ten human donors. No T-cell proliferation.</li>
        </ul>

        <h2>The Five Contenders</h2>

        <div class="platform-card jam2">
            <h3>JAM-2 <span class="tagline">"The Pragmatist"</span></h3>
            <p>Nabla Bio's JAM-2: <strong>39% hit rate</strong> for VHH-Fc antibodies, 923+ designs on 26+ targets. 57% pass <em>all</em> developability filters. They've hit GPCRs (CXCR4 at 1.4 nM), checkpoint inhibitors (PD-L1), and RTKs (TrkA at &lt;100 pM).</p>
        </div>

        <div class="platform-card chai2">
            <h3>Chai-2 <span class="tagline">"The Precision Instrument"</span></h3>
            <p>Chai Discovery's Chai-2: structural accuracy below <strong>1.7 angstrom RMSD</strong>. KRAS G12V antibody at 1.5 nM that discriminates single amino acids. The headline: a CXCR4 antibody that <strong>activates</strong> the receptor (EC50 = 164 nM)&mdash;first computational GPCR agonist.</p>
        </div>

        <div class="platform-card origin1">
            <h3>Origin-1 <span class="tagline">"The Pioneer"</span></h3>
            <p>AbSci's Origin-1: built for targets where no structural precedent exists. "Zero-prior" epitope focus. Lower hit rates (~4%), but hitting targets that fail with conventional methods. Cryo-EM validated.</p>
        </div>

        <div class="platform-card rfantibody">
            <h3>RFAntibody <span class="tagline">"The Open-Source Idealist"</span></h3>
            <p>Baker Lab's RFAntibody: <strong>MIT license</strong>, fully reproducible. Lower hit rates (~1-2%), needs 9,000+ designs per target, but rigorous validation. The genuine alternative for academic labs.</p>
        </div>

        <div class="platform-card lx2">
            <h3>Latent-X2 <span class="tagline">"The Dark Horse"</span></h3>
            <p><strong>Latent Labs' Latent-X2</strong> brings several firsts:</p>
            <ul>
                <li>50% target-level success; 26.2 pM best affinity (HDAC8)&mdash;tightest reported</li>
                <li>Only 4&ndash;24 designs per target (vs. 45&ndash;9,000+ for others)</li>
                <li><strong>First immunogenicity data:</strong> Ex vivo T-cell assays in 10 human donors</li>
                <li><strong>Macrocycle design:</strong> Same architecture generates peptide macrocycles</li>
            </ul>
        </div>

        <h2>The Head-to-Head</h2>
        <div class="chart-container">
            <h4>Hit Rate vs. Design Efficiency</h4>
            <div class="chart-wrapper"><canvas id="efficiencyChart"></canvas></div>
            <p class="source">Source: Platform publications 2024&ndash;2026</p>
        </div>

        <table>
            <thead><tr><th>Platform</th><th>Designs/Target</th><th>Best Affinity</th><th>Hit Rate</th><th>Open Source</th></tr></thead>
            <tbody>
                <tr><td><strong>JAM-2</strong></td><td>45&ndash;100</td><td>&lt;100 pM</td><td>39%</td><td>No</td></tr>
                <tr><td><strong>Chai-2</strong></td><td>50&ndash;100</td><td>453 pM</td><td>48%</td><td>No</td></tr>
                <tr><td><strong>Origin-1</strong></td><td>&lt;100</td><td>89 nM</td><td>4%</td><td>Partial</td></tr>
                <tr><td><strong>RFAntibody</strong></td><td>9,000+</td><td>1.4 nM</td><td>1&ndash;2%</td><td>Yes (MIT)</td></tr>
                <tr style="background: rgba(148, 103, 189, 0.15);"><td><strong>Latent-X2</strong></td><td><strong>4&ndash;24</strong></td><td><strong>26.2 pM</strong></td><td><strong>50%</strong></td><td>No</td></tr>
            </tbody>
        </table>

        <h2>The Immunogenicity Moment</h2>
        <p>Here's the elephant in every computational antibody room: all the hit rates in the world don't matter if patients develop anti-drug antibodies.</p>
        <p><strong>Until now, no one had tested whether AI-designed antibodies trigger immune responses.</strong></p>

        <div class="lx2-callout">
            <h3>First-Ever AI Antibody Immunogenicity Data</h3>
            <p>Latent-X2 tested 4 VHH binders in PBMCs from 10 healthy human donors:</p>
            <ul>
                <li><strong>T-cell proliferation:</strong> No increase vs. background</li>
                <li><strong>Cytokine release:</strong> No elevation detected</li>
                <li><strong>Comparison:</strong> Indistinguishable from FDA-approved caplacizumab</li>
            </ul>
        </div>

        <p><strong>Caveats:</strong> Ex vivo only, 10 donors, one target, short timepoints. This won't satisfy the FDA. But it answers: "Has anyone even <em>checked</em>?" Now someone has.</p>

        <h2>Beyond Antibodies: The Macrocycle Surprise</h2>
        <p>Latent-X2 designed macrocycles using the <em>same architecture</em> it uses for antibodies:</p>
        <table>
            <thead><tr><th>Target</th><th>Latent-X2</th><th>RaPID mRNA Display</th><th>Comparison</th></tr></thead>
            <tbody>
                <tr><td><strong>PHD2</strong></td><td>1.54 nM (10 designs)</td><td>729 nM (&gt;10<sup>12</sup> library)</td><td><strong>470x better</strong></td></tr>
                <tr><td><strong>K-Ras G12D</strong></td><td>5.43 uM (10 designs)</td><td>5.53 uM (&gt;10<sup>12</sup> library)</td><td>Comparable</td></tr>
            </tbody>
        </table>
        <p>Macrocycles can access <strong>intracellular targets</strong> that antibodies can't reach. If AI can design both antibodies <em>and</em> macrocycles from a single platform, the modality choice becomes a design parameter.</p>

        <div class="oncology-section">
            <h2>The Oncology Landscape</h2>
            <p class="target-category">Best Affinities Achieved</p>
            <table>
                <thead><tr><th>Target</th><th>Platform</th><th>Affinity</th><th>Context</th></tr></thead>
                <tbody>
                    <tr style="background: rgba(148, 103, 189, 0.15);"><td><strong>HDAC8</strong></td><td>Latent-X2</td><td><strong>26.2 pM</strong></td><td>Epigenetic; neuroblastoma</td></tr>
                    <tr><td>TrkA</td><td>JAM-2</td><td>&lt;100 pM</td><td>Tumor-agnostic approval</td></tr>
                    <tr><td>CCR8</td><td>Chai-2</td><td>453 pM</td><td>Tumor Tregs; 0 approved drugs</td></tr>
                </tbody>
            </table>
            <div class="chart-container">
                <h4>Best Binding Affinities (nM, log scale)</h4>
                <div class="chart-wrapper" style="height: 280px;"><canvas id="gpcrChart"></canvas></div>
                <p class="source">Lower values = tighter binding</p>
            </div>
        </div>

        <h2>The Caveats</h2>
        <div class="caveat-box">
            <h3>Reality Check</h3>
            <ul>
                <li><strong>No in vivo data.</strong> No mouse PK, tumor xenografts, or in vivo proof of concept.</li>
                <li><strong>Immunogenicity barely tested.</strong> 10 donors and one target isn't clinical validation.</li>
                <li><strong>Manufacturing unvalidated.</strong> Clinical-scale CHO production not demonstrated.</li>
                <li><strong>Structural validation varies.</strong> Chai-2 has 5 cryo-EM structures. Latent-X2 has zero.</li>
                <li><strong>Most aren't available.</strong> Only RFAntibody is open source.</li>
            </ul>
        </div>
        <blockquote>We've solved the "can we generate binders" problem. We haven't solved the "will they work in humans" problem.</blockquote>

        <h3>What's Actually Been Demonstrated</h3>
        <div class="pipeline-viz">
            <div class="pipeline-stage done">Hit Discovery</div>
            <div class="pipeline-stage done">Lead Optim.</div>
            <div class="pipeline-stage partial">Developability</div>
            <div class="pipeline-stage lx2-done">Ex Vivo Immuno.</div>
            <div class="pipeline-stage future">In Vivo</div>
            <div class="pipeline-stage future">IND</div>
        </div>
        <p style="font-size: 0.85em; color: #666; text-align: center;">Latent-X2 is the only platform with ex vivo immunogenicity data. In vivo validation remains ahead for all.</p>

        <h2>So What?</h2>
        <p><strong>For big pharma:</strong> Computational antibody design will be table stakes in three years.</p>
        <p><strong>For biotechs:</strong> If your differentiation is "we have immunogenicity data," you now have exactly one competitor.</p>
        <p><strong>For VCs:</strong> Look for efficiency metrics, immunogenicity data, macrocycle capability, and structural validation.</p>
        <p><strong>For academics:</strong> RFAntibody exists. The barrier just dropped to "can you run Python and validate 9,000 candidates."</p>

        <h2>Where This Goes</h2>
        <p>Twenty-four months from now, I expect:</p>
        <ul>
            <li><strong>IND-enabling data</strong> from at least one platform&mdash;with immunogenicity studies</li>
            <li><strong>Ex vivo immunogenicity testing</strong> becoming standard</li>
            <li><strong>Macrocycle design</strong> offered by at least two more platforms</li>
            <li><strong>Integration with AI affinity maturation</strong> for end-to-end pipelines</li>
        </ul>
        <p>The $200 billion antibody market isn't going away. But how we populate it is about to change fundamentally.</p>

        <div class="pdf-notice" style="margin-top: 2em;">
            <p><strong>Want more depth?</strong> For detailed methodology comparisons, additional oncology targets, and full citations, <a href="/files/v5_denovo_antibody_design_comparison.pdf" target="_blank">read the comprehensive technical report (PDF)</a>.</p>
        </div>

        <div class="footer">
            <p>Data sources: JAM-2, Chai-2, Origin-1, RFAntibody, and Latent-X2 publications (2024&ndash;2026). Open Targets Platform for disease associations.</p>
            <p style="margin-top: 1em;"><a href="/" style="color: var(--accent);">&larr; Back to inventcures.github.io</a></p>
        </div>
    </article>

    <script>
        Chart.defaults.font.family = 'Georgia, serif';
        Chart.defaults.font.size = 12;
        const efficiencyCtx = document.getElementById('efficiencyChart').getContext('2d');
        new Chart(efficiencyCtx, {
            type: 'scatter',
            data: {
                datasets: [
                    { label: 'JAM-2', data: [{x: 70, y: 39}], backgroundColor: '#E63946', pointRadius: 14 },
                    { label: 'Chai-2', data: [{x: 75, y: 48}], backgroundColor: '#457B9D', pointRadius: 14 },
                    { label: 'Origin-1', data: [{x: 100, y: 4}], backgroundColor: '#2A9D8F', pointRadius: 12 },
                    { label: 'RFAntibody', data: [{x: 9000, y: 1.5}], backgroundColor: '#E9C46A', pointRadius: 12 },
                    { label: 'Latent-X2', data: [{x: 12, y: 50}], backgroundColor: '#9467BD', pointRadius: 18 }
                ]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                scales: {
                    x: { type: 'logarithmic', title: { display: true, text: 'Designs Required per Target (log scale)' }, min: 5, max: 15000 },
                    y: { title: { display: true, text: 'Hit Rate (%)' }, min: 0, max: 60 }
                },
                plugins: { legend: { position: 'right' } }
            }
        });
        const gpcrCtx = document.getElementById('gpcrChart').getContext('2d');
        new Chart(gpcrCtx, {
            type: 'bar',
            data: {
                labels: ['HDAC8 (Latent-X2)', 'CCR8 (Chai-2)', 'CXCR4 (JAM-2)', 'CXCR4 agonist (Chai-2)', 'GPRC5D (Chai-2)'],
                datasets: [{ data: [0.0262, 0.453, 1.4, 164, 189], backgroundColor: ['#9467BD', '#457B9D', '#E63946', '#457B9D', '#457B9D'] }]
            },
            options: {
                indexAxis: 'y', responsive: true, maintainAspectRatio: false,
                scales: { x: { type: 'logarithmic', title: { display: true, text: 'Binding Affinity (nM) - lower is better' }, min: 0.01, max: 500 } },
                plugins: { legend: { display: false } }
            }
        });
    </script>
</body>
</html>
